Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
12:30am, Friday, 30'th Aug 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withd
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
04:30am, Wednesday, 21'st Aug 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician exp
Asure Acquires HIRECLICK, Expands HCM Suite with an Intuitive, AI-Powered Applicant Tracking System
10:55am, Thursday, 15'th Aug 2024
Advanced ATS solution helps small and mid-size businesses to streamline talent acquisition in competitive job markets Advanced ATS solution helps small and mid-size businesses to streamline talent acq
Top Wall Street Forecasters Revamp Paycor HCM Price Expectations Ahead Of Q4 Earnings
09:45am, Wednesday, 14'th Aug 2024
Paycor HCM, Inc. PYCR is expected to release earnings results for its fourth quarter, after the closing bell on Wednesday, Aug. 14.
Hutchmed Growing Sales By 64% In H1 2024
02:08am, Friday, 09'th Aug 2024
Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of on
HUTCHMED (China) Limited (HCM) Q2 2024 Earnings Call Transcript
01:55pm, Wednesday, 31'st Jul 2024
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants David Ng - Head:Investor Relations Wei-Guo Su - Chief Executive Officer & Chief Sc
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application
HUTCHMED to Announce 2024 Half-Year Financial Results
04:30am, Wednesday, 26'th Jun 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six
HCM Digital World Class Matrix™ Identifies Software Innovations and Leading Providers
10:54am, Tuesday, 25'th Jun 2024
MIAMI--(BUSINESS WIRE)--The Hackett Group, Inc. (NASDAQ: HCKT), released its first Digital World Class Matrix™ focused on the human capital management (HCM) software market – a growing segment of
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
05:30am, Monday, 24'th Jun 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
04:00pm, Friday, 21'st Jun 2024
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
08:00pm, Sunday, 16'th Jun 2024
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
08:00pm, Thursday, 06'th Jun 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clini
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
08:00pm, Sunday, 02'nd Jun 2024
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
08:00pm, Thursday, 23'rd May 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data fro
